Trial Profile
A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients With CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Aug 2023
Price :
$35
*
At a glance
- Drugs Pivekimab sunirine (Primary)
- Indications Acute myeloid leukaemia; Blastic plasmacytoid dendritic cell neoplasm; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Haematological malignancies; Myelodysplastic syndromes; Myeloproliferative disorders; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; First in man; Registrational; Therapeutic Use
- Acronyms CADENZA
- Sponsors ImmunoGen
- 01 Aug 2023 Following indications have been added- blast phase-Chronic-myeloid-leukaemia (BP-CML), Chronic-myelomonocytic-leukaemia (CMML), Myeloproliferative-disorders (MPN).
- 01 Aug 2023 Status changed from recruiting to active, no longer recruiting.
- 31 Jul 2023 According to an ImmunoGen media release, the company enrolled last patient in the pivotal de novo frontline BPDCN cohort at the end of the second quarter.